PLBD2

Across TCGA pan-cancer cohorts, PLBD2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PLBD2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher PLBD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLBD2 expression acts as an unfavorable survival marker, although some lineages such as SCLC and SKCM show a favorable association.

KICH, LUSC, and SCLC are the cancer types where PLBD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUSC	OS	Median	All	0.168	0.659	.027	9	view →
SCLC	DFS	Median	II,III,IV	1.000	0.349	.022	7	view →
STAD	OS	Median	All	0.443	0.734	.018	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ESCA	OS	Median	II,III,IV	0.413	0.691	.048	3	view →
SKCM	DFS	Median	IV	1.000	0.261	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PLBD2–KICH (DFS)

Open the KICH breakdown →